(Q37098220)

randomized controlled trial

18 August 2017

1 reference

17 November 2019

multicenter study report

1 reference

PubMed publication ID

23856559

1 reference

PubMed publication ID

23856559

title

Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial (English)

1 reference

chronic progressive multiple sclerosis

18 August 2017

0 references

0 references

1 reference

PubMed

cannabinoid receptor agonists

30 June 2019

1 reference

2 October 2019

1 reference

7 November 2019

1 reference

17 November 2019

6

David Miller

1 reference

18 August 2017

John Zajicek

1

1 reference

18 August 2017

Susan Ball

2

1 reference

18 August 2017

David Wright

3

1 reference

18 August 2017

Jane Vickery

4

1 reference

18 August 2017

Andrew Nunn

5

1 reference

18 August 2017

Mayam Gomez Cano

7

1 reference

18 August 2017

David McManus

8

1 reference

18 August 2017

Sharukh Mallik

9

1 reference

18 August 2017

Jeremy Hobart

10

1 reference

18 August 2017

CUPID investigator group

11

1 reference

18 August 2017

13 July 2013

1 reference

18 August 2017

1 September 2013

5 references

25 April 2019

30 June 2019

2 October 2019

7 November 2019

17 November 2019

6 references

18 August 2017

25 April 2019

30 June 2019

2 October 2019

7 November 2019

17 November 2019

12

1 reference

18 August 2017

9

1 reference

18 August 2017

857-865

1 reference

Multiple sclerosis and extract of cannabis: results of the MUSEC trial.

18 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744749

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744749

Improving the evaluation of therapeutic interventions in multiple sclerosis: the role of new psychometric methods

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744749

Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744749

Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744749

Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744749

Accurate, robust, and automated longitudinal and cross-sectional brain change analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744749

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744749

Effects of cannabinoids on LPS-stimulated inflammatory mediator release from macrophages: involvement of eicosanoids.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744749

Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744749

The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744749

Longitudinal measurement invariance of the Multiple Sclerosis Walking Scale-12.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744749

Therapeutic action of cannabinoids in a murine model of multiple sclerosis.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744749

Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744749

Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744749

Normalized accurate measurement of longitudinal brain change

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744749

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

3 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970159-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S1474-4422(13)70159-5

1 reference

18 August 2017

1 reference

18 August 2017

PubMed publication ID

23856559

1 reference